Abyssinia Biologics

What Abyssinia Biologics does

Abyssinia Biologics, Inc. (also operating as Abyssinia Biosciences) is a privately held, preclinical-stage biotechnology company founded in 2017 and headquartered at 855 Boylston St. in Boston, Massachusetts. The company is developing a pipeline of monoclonal antibodies that selectively bind to toxic, misfolded soluble amyloid-beta (Aβ) oligomers implicated in Alzheimer's disease, on the thesis that soluble oligomers — rather than amyloid plaques — are the primary driver of synaptic dysfunction and neurodegeneration. Its lead candidates, ABY-1125 and ABY-1220, are reported to bind epitopes present only in oligomers, a profile the company states no other monoclonal antibody in clinical development possesses; the company positions this as a path to clinical efficacy with reduced risk of ARIA (Amyloid-Related Imaging Abnormalities).

The company's strategic framing extends beyond therapy into prevention (an immune-based vaccine concept aimed at neutralizing oligomers before plaque formation) and diagnosis (plasma- and CSF-based biomarker monitoring of soluble Aβ). Operationally, Abyssinia runs a lean, virtual organization of 1–10 employees, supported by a Scientific Advisory Board that includes Harvard Medical School faculty and a former CSO/CTO of Sarepta and Elan. The company has no commercial products, no disclosed revenue, and no pricing model, consistent with its preclinical status. Its only disclosed funding to date is approximately $766,500 across three rounds between 2018 and 2024, including a $750,000 round in January 2024 and two small Maine Technology Institute awards in 2018 and 2020.

Name

Abyssinia Biologics

Legal name

Abyssinia Biologics, Inc.

Website

https://aby-bio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Abyssinia Biologics is a preclinical-stage Boston biotech developing monoclonal antibodies (ABY-1125, ABY-1220) that selectively bind toxic soluble amyloid-beta oligomers to treat and potentially prevent Alzheimer's disease.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Therapeutic Antibodies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Monoclonal antibody therapy
• Alzheimer's disease therapeutics
• Amyloid-beta oligomer targeting
• Neurodegenerative disease biologics
• Preclinical antibody development

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels1 record

Core offering

Abyssinia Biologics is a preclinical-stage biotechnology company developing monoclonal antibody (mAb) therapeutics that selectively bind to toxic soluble amyloid-beta (Aβ) oligomers implicated in Alzheimer's disease. Its lead candidates, ABY-1125 and ABY-1220, target epitopes unique to oligomers and are designed to avoid plaque-related side effects such as ARIA. The company is also pursuing a preventive vaccine approach and minimally invasive biomarker diagnostics for Alzheimer's.

Product overview

Abyssinia Biologics is a biotech company developing a pipeline of monoclonal antibodies targeting neurodegenerative diseases. The company's core products are lead candidates ABY-1125 and ABY-1220, which are monoclonal antibodies that selectively bind to toxic soluble amyloid-beta (Aβ) oligomers implicated in Alzheimer's disease. Unlike plaque-targeting therapies, these oligomer-selective antibodies aim to provide greater clinical benefits with fewer side effects including ARIA (Amyloid-Related Imaging Abnormalities).

Differentiator

Problem solved

Functional benefit

Products and services

• ABY-1125 ABY-1125 is a monoclonal antibody that selectively binds to toxic misfolded forms of amyloid-beta oligomers. In preclinical studies, it has demonstrated significantly greater selectivity for toxic oligomers in Alzheimer's disease brain samples compared to other amyloid-targeting antibody therapies in clinical development. It is being developed for the treatment of Alzheimer's disease.
• ABY-1220 ABY-1220 is a monoclonal antibody that selectively binds to toxic misfolded forms of amyloid-beta. It binds to an epitope that is only present in oligomers and that no other monoclonal antibodies bind to, distinguishing it from competing amyloid-targeting antibody therapies. It is being developed for the treatment of Alzheimer's disease.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Eisai: Co-developer of Leqembi and longstanding AD franchise incumbent. Directly competes in the same anti-Aβ mAb space and a likely strategic counterparty for in-licensing differentiated oligomer assets.
• Biogen: Developer of Aduhelm and partner with Eisai on Leqembi (lecanemab). Broad neurodegeneration pipeline and recurring interest in next-generation anti-amyloid programs make it a key incumbent benchmark and potential partner.
• Eli Lilly: Approved Kisunla (donanemab) and is the incumbent anti-amyloid leader with deep AD pipeline. Defines the efficacy/safety benchmark any oligomer-selective startup must beat and represents the most likely acquirer of differentiated oligomer assets.
• Roche / Genentech: Developed crenezumab and gantenerumab (both failed in pivotal trials), and continues pursuing next-generation AD therapies. A broad incumbent whose past anti-amyloid setbacks inform the strategic playbook oligomer-selective startups must differentiate against.

Direct peers

• Prothena Corporation: Clinical-stage biotech developing multiple neurodegenerative disease mAbs targeting misfolded/oligomeric proteins, including PRX012 (anti-Aβ) and tau programs. Directly comparable scientific approach targeting toxic protein conformers.
• Acumen Pharmaceuticals: Clinical-stage biotech developing ACU193 (sapablursen), a monoclonal antibody selectively targeting soluble Aβ oligomers for Alzheimer's disease. Closest direct mechanistic peer to Abyssinia's ABY-1125/ABY-1220.

Emerging players

• Alector: Clinical-stage biotech developing neuroimmunology/neurodegeneration antibodies (e.g., TREM2, progranulin programs). Comparable antibody-platform approach in neurodegeneration though targeting innate immunity rather than Aβ oligomers.
• Cassava Sciences: Late-stage clinical biotech developing simufilam for Alzheimer's with a different (filamin A) mechanism. Comparable size, stage and clinical-trial-risk profile to Abyssinia's preclinical positioning in the broader AD field.
• Denali Therapeutics: Clinical-stage neurodegeneration biotech with multiple CNS programs leveraging antibody engineering and biomarker-guided development. Comparable platform philosophy and likely partner/acquirer candidate for selective oligomer assets.
• Cognition Therapeutics: Clinical-stage biotech developing sigma-2 receptor modulators (CT1812) for Alzheimer's that act on oligomer-driven synaptic dysfunction. Different mechanism but complementary oligomer-pathway thesis and comparable preclinical-to-clinical scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aby-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abyssinia Biologics